Research location

South Yarra

Australia

Published trials7

Site observations7

Linked trials published7

Page1 / 1

Research activity in South Yarra

Australia

CureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 7 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in South Yarra

7 linked trials · page 1 of 1

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702 · 2011-12-01 · 1 site observation

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.NCT00461266 · 2007-04-01 · 1 site observation

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.NCT00326963 · 2006-03-01 · 1 site observation

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected SubjectsNCT00262522 · 2005-11-01 · 1 site observation

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)NCT00028301 · 2001-02-01 · 1 site observation

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected PatientsNCT00005918 · 2000-06-01 · 1 site observation

T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV DrugsNCT00021554 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.